Imara Announces Stockholder Approval of Merger With Enliven
With the IPO market still depleted, Enliven, a precision oncology company, has found a different path to the Nasdaq stock exchange.
Boulder, CO and Boston, MA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. (Nasdaq: IMRA) (Imara) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Enliven’s pipeline of precision oncology product candidates. Enliven is advancing two parallel lead product candidates: ELVN-001, a highly selective small molecule BCR-ABL inhibitor designed to address the challenges that limit the efficacy, tolerability and convenience of currently available adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML), and ELVN-002, a potent, selective and irreversible HER2 and pan-HER2 mutant kinase inhibitor for the treatment of HER2 mutant lung cancer and other HER2-driven tumor types.
After whittling itself down from 41 to just six employees following a fruitless readout on its blood disorder drug earlier this year, Imara has found a buyer to exchange the drug for cash.
Imara Inc (NASDAQ: IMRA) has agreed to divest tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuticals Inc.
Imara is the latest biotech to cut jobs this year, revealing on Friday plans to lay off 83% of its workforce after disappointing clinical results led the company to shelve its top drug candidate.
An Imara drug that hits a novel target to treat rare, inherited hemoglobin disorders has failed two mid-stage studies, one for sickle cell disease and the other for beta thalassemia. The biotech company said Tuesday it will discontinue both programs.
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary...
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m. ET.